Macrolide antibiotics and bronchiolitis obliterans following lung transplantation

References

• Macklem PT. The physiology of small airways. Am. J. Respir. Crit. Care Med. 157(5), S181–S183 (1998).
   PubMed Web of Science ®Google Scholar
• Trulock EP, Edwards LB, Taylor DO et al. The registry of the International Society for Heart and Lung transplantation: twentieth official heart-lung report – 2003. J. Heart Lung Transplant. 22, 625–653 (2003).
   PubMed Web of Science ®Google Scholar
• Valentine VG, Robbins RC, Berry GL. Actuarial survival of heart–lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J. Heart Lung Transplant. 15, 371–383 (1996).
   PubMedGoogle Scholar
• Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am. J. Respir. Crit. Care Med. 166, 440–444 (2002).
   PubMed Web of Science ®Google Scholar
• Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am. J. Respir. Crit. Care Med. 168, 1277–1292 (2003).
   PubMed Web of Science ®Google Scholar
• Tamm M, Sharples L, Higenbottam T, Steward S, Wallwotk J. Bronchiolitis obliterans syndrome (BOS) following heart–lung transplantation. Transpl. Int. 9, S299–S302 (1996).
   Google Scholar
• Glanville AR, Baldwin JC, Burke CM, Theodore J, Robin ED. Obliterative bronchiolitis after heart–lung transplantation: apparent arrest by augmented immunosuppresion. Ann. Intern. Med. 107, 300–304 (1987).
   PubMedGoogle Scholar
• Stewart S. The pathology of lung transplantation. Semin. Diagn. Pathol. 9, 210–219 (1992).
   PubMedGoogle Scholar
• Pomerance A, Madden B, Burke MM, Yacoub MH. Transbronchial biopsy in heart and lung transplantation: clinicopathological correlations. J. Heart Lung Transplant. 14, 761–763 (1995).
   PubMed Web of Science ®Google Scholar
• Cooper JD, Billingham M, Egan T et al. A working formulation for the standardisation of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J. Heart Lung Transplant. 12, 713–716 (1993).
   PubMed Web of Science ®Google Scholar
• Estenne M, Maurer J, Boehler A et al. Bronchiolitis obliterans syndrome 2001 an update of the diagnostic criteria. J. Heart Lung Transplant. 21, 297–310 (2002).
   PubMed Web of Science ®Google Scholar
• Bankier AA, Muylem AV, Knoop C, Estenne M, Gevenois PA. BOS in heart–lung tranplant recipients: diagnosis with expiratory CT. Radiology 218, 533–539 (2001).
   PubMed Web of Science ®Google Scholar
• Heng D, Sharples LD, McNeil K, Stewart S, Wreghitt T, Wallwork J. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis and risk factors. J. Heart Lung Transplant. 17, 1255–1263 (1998).
   PubMed Web of Science ®Google Scholar
• Hussain AN, Siddiqui MT, Holmes EW et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 159, 829–833 (1999).
   PubMedGoogle Scholar
• Ross DJ, Marchevsky A, Kramer M, Kass RM. ‘Refractoriness’ of airflow obstruction associated with isolated lymphocytic bronchiolitsis/bronchitis in pulmonary allografts. J. Heart Lung Transplant. 16, 832–838 (1997).
   PubMedGoogle Scholar
• SivaSai KS, Smith MA, Poindexter NJ et al. Indirect recognition of donor HLA class I peptides in lung transplantation recipients with bronchiolitis obliterans syndrome. Transplantation 67, 1094–1098 (1999).
   PubMedGoogle Scholar
• Lu KC, Jaramillo A, Mendeloff EN et al. Concomitant allorecognition of mismatched donor HLA class I- and II-derived peptides in paediatric lung transplant recipients with bronchiolitis obliterans syndrome. J. Heart Lung Transplant. 22, 35–43 (2003).
   PubMedGoogle Scholar
• Fisher AJ, Rutherford RM, Bozzino J, Parry G, Dark JH, Corris PA. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am. J. Transplant. 5, 537–543 (2005).
   PubMed Web of Science ®Google Scholar
• Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J. Thorac. Cardiovasc. Surg. 114, 195–202 (1997).
   PubMed Web of Science ®Google Scholar
• Duncan SR, Paradis IL, Yousem SA et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am. Rev. Respir. Dis. 146, 1419–1425 (1992).
   PubMedGoogle Scholar
• Bando K, Paradis IL, Similo S. Obliterative bronchiolitis after lung and heart–lung transplantation: an analysis of risk factors and management. J. Thorac. Cardiovasc. Surg. 110, 4–14 (1995).
   PubMed Web of Science ®Google Scholar
• Ettinger NA, Bailey TC, Trulock EP et al. Cytomegalovirus infection and pneumonitis: impact after isolated lung transplantation. Am. Rev. Respir. Dis. 147, 1017–1023 (1993).
   PubMed Web of Science ®Google Scholar
• Tamm M, Aboyoun CL, Chhajed PN, Rainer S, Malouf MA, Glanville AR. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 170, 1120–1123 (2004).
   PubMed Web of Science ®Google Scholar
• Novick RJ, Bennett LE, Meyer DM, Hosenpud JD. Influence of graft ischaemic time and donor age on survival after lung transplantation. J. Heart Lung Transplant. 18, 425–431 (1999).
   PubMed Web of Science ®Google Scholar
• Davis RD, Lau CL, Eubanks S et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. Am. J. Respir. Crit. Care Med. 168, 121–125 (2003).
   PubMedGoogle Scholar
• Girgis RE, Tu I, Berry GJ et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J. Heart Lung Transplant. 15, 1200–1208 (1996).
   PubMed Web of Science ®Google Scholar
• Gerhadt S, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans. Am. J. Resp. Crit. Care Med. 166, 440–444 (2002).
   PubMedGoogle Scholar
• Page RL, Ruscin J, Fish D, Lapointe M. Possible interactions between intravenous azithromycin and oral cyclosporin. Pharmacotherapy 21, 1436–1443 (2001).
   PubMedGoogle Scholar
• Verleden GM, DuPont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 77, 1465–1467 (2004).
   PubMed Web of Science ®Google Scholar
• Khalid M, Al Saghir A, Saleemi S et al. Azithromycin in bronchiolitis complicating bone marrow transplantation: a preliminary study. Eur. Respir. J. 25, 490–493 (2005).
   PubMed Web of Science ®Google Scholar
• Yates B, Murphy DM, Forrest IA et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 172, 772–775 (2005).
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Schatz M, Sperling W, Simon RA, Stevenson DD. Efficacy of troleandomycin in out-patients with severe, corticosteroid dependent asthma. J. Allergy Clin. Immunol. 66, 438–446 (1980).
   PubMedGoogle Scholar
• Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low dose erythromycin. Am. J. Resp. Crit. Care Med. 157, 1829–1832 (1998).
   PubMed Web of Science ®Google Scholar
• Kudoh S, Uetake T, Hagiwara K et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 4, 324–329 (1987).
   Google Scholar
• Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J. Antimicrob. Chemother. 54, 21–28 (2004).
   PubMed Web of Science ®Google Scholar
• Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long-term azithromycin therapy in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360, 978–984 (2002).
   PubMed Web of Science ®Google Scholar
• Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57, 212–216 (2002).
   PubMed Web of Science ®Google Scholar
• Konno S, Asano K, Kurokawa M, Ikeda K, Okamoto K, Adachi M. Anti-asthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. Int. Arch. Allergy Immunol. 105, 308–316 (1994).
   PubMed Web of Science ®Google Scholar
• Amayasu H, Yoshida S, Ebana S et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann. Allergy Asthma Immunol. 84, 594–598 (2000).
   PubMed Web of Science ®Google Scholar
• Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am. J. Rhinol. 14, 143–148 (2000).
   PubMedGoogle Scholar
• Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomised controlled trial. J. Am. Med. Assoc. 290, 1749–1756 (2003).
   PubMed Web of Science ®Google Scholar
• Reynaurd-Gaubert M, Marin V, Thirion X et al. Upregulation of chemokines in bronchalveolar fluid as a predictive marker of post-transplant airway obliteration. J. Heart Lung Transplant. 21, 721–730 (2002).
   PubMedGoogle Scholar
• Kurdowska A, Noble JM, Griffith DE. The effect of azithromycin and chlarithromycin on ex vivo interleukin (IL)-8 release from whole blood and IL-8 production by human alveolar macrophages. J. Antimicrob. Chemother. 47, 867–870 (2001).
   PubMed Web of Science ®Google Scholar
• Koch CC, Esteban DJ, Chin AC et al. Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumonia. J. Antimicrob. Chemother. 46, 19–26 (2000).
   PubMedGoogle Scholar
• Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin-1β, TNF-α and IL-8 in bronchoalveolar fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 63, 42–48 (1996).
   PubMed Web of Science ®Google Scholar
• Fujii T, Kadota J, Kawakami K et al. Long-term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 50, 1246–1252 (1995).
   PubMed Web of Science ®Google Scholar
• Fujii T, Kadota J, Morikawa T et al. Inhibitory effect of erythromycin on interleukin-8 production by 1α, 25-dihydroxyvitamin D3-stimulated THP-1 cells. Antimicrob. Agents Chemother. 40, 1548–1551 (1996).
   PubMed Web of Science ®Google Scholar
• Takizawa H, Desaki M, Ohtoshi T et al. Erythromycin suppresses interleukin-6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem. Biophys. Res. Commun. 210, 781–786 (1995).
   PubMed Web of Science ®Google Scholar
• Khan AA, Slifer TR, Araujo FG, Remington JS. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int. J. Antimicrob. Agents 11, 121–132 (1999).
   PubMed Web of Science ®Google Scholar
• Matsuoaka N, Eguchi K, Kawakami A et al. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin. Exp. Immunol. 104, 501–508 (1996).
   PubMedGoogle Scholar
• Mukae H, Kadota J, Ashitani J et al. Elevated levels of soluble adhesion molecules in serum of patients with diffuse panbronchiolitis. Chest 112, 1615–1621 (1997).
   PubMedGoogle Scholar
• Desaki M, Takizawa H, Ohtoshi T et al. Erythromycin suppresses nucler factor-κB and activator protein-1 activation in human bronchial cells. Biochem. Biophys. Res. Commun. 267, 124–128 (2000).
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan A, Stecenko AA, King G et al. Exaggerated activation of nuclear factor-κB and altered I-κB processing in cystic fibrosis bronchial epithelial cells. Am. J. Respir. Cell. Mol. Biol. 23, 396–403 (2000).
   PubMed Web of Science ®Google Scholar
• Culic O, Erakovic V, Cepelak I et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur. J. Pharmacol. 450, 277–289 (2002).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Asada Y, Ikeda K, Oshima T, Takasaka T. Inhibitory effect of erythromycin on interleukin-8 secretion from exudative cells in the nasal discharge of patients with chronic sinusitis. Laryngoscope 109, 407–410 (1999).
   PubMedGoogle Scholar
• Ianaro A, Ialenti A, Maffia P et al. Anti-inflammatory activity of macrolide antibiotics. J. Pharmacol. Exp. Ther. 292, 156–163 (2000).
   PubMed Web of Science ®Google Scholar
• Levert H, Gressier B, Moutard I et al. Azithromycin impact on neutrophil oxidative metabolism depends on exposure time. Inflammation 22, 191–201 (1998).
   PubMed Web of Science ®Google Scholar
• Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45, 1930–1933 (2001).
   PubMed Web of Science ®Google Scholar
• Ward C, Camara M, Forrest I et al. Preliminary findings of quorum signal molecules in clinically stable lung allograft recipients. Thorax 58, 444–446 (2003).
   PubMed Web of Science ®Google Scholar
• Kobayashi H. Airway biofilm disease. Int. J. Antimicrob. Agents 17, 351–356 (2001).
   PubMedGoogle Scholar
• Glanville AR, Gencay M, Tamm M et al. Chlamydia pneumoniae infection after lung transplantation. J. Heart Lung Transplant. 24, 131–136 (2005).
   PubMed Web of Science ®Google Scholar
• Kotsimbos TC, Snell GI, Levvey et al. Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 79, 269–275 (2005).
   PubMed Web of Science ®Google Scholar
• Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma. Chest 121, 1782–1788 (2002).
   PubMed Web of Science ®Google Scholar
• Dhir R, Richter JE. Erythromycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis. J. Clin. Gastroenterol. 38, 237–242 (2004).
   PubMed Web of Science ®Google Scholar
• Kanai K, Asano K, Hisamitsu T, Suzaki H. Suppression of matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro. Eur. Respir. J. 23, 671–678 (2004).
   PubMed Web of Science ®Google Scholar
• Kanai K, Asano K, Hisamitsu T, Suzaki H. Suppression of matrix metalloproteinase-9 production from neutrophils by a macrolide antibiotic, roxithromycin, in vitro. Mediators Inflamm. 13, 313–319 (2004).
   PubMed Web of Science ®Google Scholar
• Kadota J, Mukae H, Ishii H et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir. Med. 97, 844–850 (2003).
   PubMed Web of Science ®Google Scholar
• Verleden GM, DuPont LJ, Van Raemdonck DE. Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal? Eur. Respir. J. 25, 221–224 (2005).
   PubMed Web of Science ®Google Scholar
• Egan JJ. Obliterative bronchiolitis after lung transplantation. Am. J. Respir. Crit. Care Med. 170, 931–932 (2004).
   Google Scholar